FY2024 EPS Estimates for Liquidia Boosted by HC Wainwright

Liquidia Co. (NASDAQ:LQDA) – HC Wainwright increased their FY2024 earnings per share (EPS) estimates for Liquidia in a note issued to investors on Thursday, November 14th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($1.51) for the year, up from their previous forecast of ($1.54). HC Wainwright has a “Buy” rating and a $29.00 price objective on the stock. The consensus estimate for Liquidia’s current full-year earnings is ($1.55) per share. HC Wainwright also issued estimates for Liquidia’s FY2025 earnings at ($1.62) EPS and FY2028 earnings at ($0.16) EPS.

Several other equities analysts also recently commented on the company. Scotiabank began coverage on Liquidia in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $30.00 price target on the stock. Lifesci Capital assumed coverage on Liquidia in a report on Thursday, October 3rd. They set an “outperform” rating and a $30.00 price target on the stock. BTIG Research reduced their price objective on Liquidia from $29.00 to $25.00 and set a “buy” rating for the company in a research report on Monday, August 19th. Raymond James raised Liquidia from an “outperform” rating to a “strong-buy” rating in a research report on Monday, August 19th. Finally, Bank of America reduced their price objective on Liquidia from $24.00 to $23.00 and set a “buy” rating for the company in a research report on Tuesday, August 20th. One analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $24.00.

Liquidia Stock Up 3.5 %

Shares of LQDA stock opened at $10.16 on Monday. Liquidia has a 12 month low of $6.33 and a 12 month high of $16.99. The business’s 50 day moving average is $10.53 and its two-hundred day moving average is $11.44. The company has a market cap of $859.94 million, a PE ratio of -6.23 and a beta of 0.21.

Insider Buying and Selling

In other Liquidia news, CFO Michael Kaseta sold 3,892 shares of Liquidia stock in a transaction on Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $43,240.12. Following the completion of the transaction, the chief financial officer now directly owns 311,076 shares of the company’s stock, valued at approximately $3,456,054.36. This trade represents a 1.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Caligan Partners Lp acquired 150,000 shares of the business’s stock in a transaction on Friday, August 30th. The shares were bought at an average cost of $9.51 per share, with a total value of $1,426,500.00. Following the completion of the acquisition, the director now owns 6,994,997 shares of the company’s stock, valued at approximately $66,522,421.47. This trade represents a 2.19 % increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 21,551 shares of company stock valued at $236,021 over the last ninety days. 30.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Quest Partners LLC bought a new position in shares of Liquidia during the second quarter valued at $27,000. Hilltop National Bank bought a new position in shares of Liquidia during the second quarter valued at $33,000. Deuterium Capital Management LLC bought a new position in shares of Liquidia during the second quarter valued at $120,000. Clear Harbor Asset Management LLC bought a new position in shares of Liquidia during the third quarter valued at $100,000. Finally, Signaturefd LLC lifted its holdings in shares of Liquidia by 38,400.0% during the third quarter. Signaturefd LLC now owns 10,010 shares of the company’s stock valued at $100,000 after acquiring an additional 9,984 shares during the period. 64.54% of the stock is owned by institutional investors.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).